Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results


TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business.

Read more:
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Related Posts